OTLK Company Profile and Key Details

Outlook Therapeutics, Inc. (NASDAQ:OTLK) closed at $0.21 USD, gaining $0.01 (5.00%) from the previous close of $0.20. The stock is currently within 5% of its 52-week low $0.20 and $3.39. With a market capitalization of about $8.56 million, Outlook Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.08). Key stats such as the average daily volume over the past year has been around 5.33 million shares, in line with its 52-week average. Headquartered in Iselin, NJ, Outlook Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Robert Charles Jahr, the company employs approximately 23 people and listed since June 14, 2016. Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications.

OTLK has shown weak momentum, losing -9.44% over the past week and -60.31% over the past quarter, though year-to-date performance is down -67.09%. Short-term trend indicators are bullishly aligned (SMA20 1.02%, SMA50 -48.54%, SMA200 -70.2%). The stock’s 14-day RSI is 38.56 (weak momentum), while the ATR of 0.06 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -87.22% below its high and over 14.0% above its low. Average 10-day trading volume of 5.16 million shares is in line with the 3-month average of 5.37 million, indicating normal recent market interest.

Outlook Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.80. This means the shares are trading below this model’s fair value.

Outlook Therapeutics, Inc. has 44.42 million shares outstanding. The public float is 24.35 million shares, elevated short interest at 6.71% of float. This equals 2.35 million shares. The short ratio is 2.7 days. Institutional investors hold 32.29% of the float. Insiders own 36.39%. Sukhtian Ghiath M. holds 27.83 million shares, Mohan Pankaj has 7.06 million shares and Syntone Ventures LLC has 1.07 million shares.

Outlook Therapeutics, Inc. generated EPS of -$1.09 over the past year. Five-year average earnings growth is 33.18%. Wall Street analysts project EPS growth of 56.24% annually over the next five years. The latest quarter delivered EPS of -$0.22. The next quarter is forecast at -$0.17. Next year's EPS is expected at $33.33. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 3 Buy ratings, 8 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $10.00 to $0.50. The high target offers 4900.0% upside. The low target suggests 150.0% downside. The mean target is $3.77. This offers 1785.0% upside. Outlook Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended December 19, 2025, missed forecasts by -4.35%. The prior quarter beat by 4.76%. Over the last six quarters, Apple has recorded several small beats. These include -21.7% in August 14, 2024.

Our AI price prediction model suggests that Outlook Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 21.15%, with price expected at $0.24 by April 07, 2026, within a range of $0.20 to $0.28 3-Month Outlook: Projected rise of 81.73%, reaching $0.36 by June 22, 2026, with a range of $0.18 to $0.55. 1-Year Outlook: Projected gain of 192.78%, with price at $0.58 by March 24, 2027, within a range of $0.00 to $0.00.

Outlook Therapeutics, Inc. (NASDAQ:OTLK) shares are down -67.09% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Outlook Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.12. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $11.07, suggesting 5488.09% upside. Our AI forecast model points to short-term strength (21.15% over two weeks), a medium-term rise (81.73% over three months), and a longer-term gain (192.78% over one year), with expected trading ranges indicating moderate volatility.

Outlook Therapeutics, Inc. trades at a P/E ratio of -0.12, slightly below the S&P 500 average, with a price-to-sales ratio of 42.55 The P/FCF stands at -0.0, also below market averages.